Exhibitors Search
HAPLNSCIENCE
Booth no.
E41/H60
| Exhibition | PARTNERING |
|---|---|
| Country | Korea, South |
| Address | 398 Simin-daero, Dongan-gu, Anyang-si, Gyeonggi-do, Republic of Korea |
| Tel (Rep.) | 010-3159-3708 |
| Website | http://haplnscience.com |
Company Introduction
HaplnScience, Inc. is a bio-venture company established in late 2018
with the aim to develop fundamental treatments for aging-related diseases.
We will contribute to the health and well-being of humankind by restoring the damaged or
degenerated tissue with aging through research on the unique mechanism of ‘rhHAPLN1’
and its development as a breakthrough anti-aging therapy.
with the aim to develop fundamental treatments for aging-related diseases.
We will contribute to the health and well-being of humankind by restoring the damaged or
degenerated tissue with aging through research on the unique mechanism of ‘rhHAPLN1’
and its development as a breakthrough anti-aging therapy.
Promotional video
Exhibit Item
We are developing disease-modifying therapies that leverage recombinant human HAPLN1 (rhHAPLN1)a protein with tissue-regenerative and rejuvenating activity?to fundamentally treat chronic obstructive pulmonary disease (COPD) and osteoarthritis (OA). Our COPD candidate (HS-401) targets emphysema-associated disease and is designed to regenerate lung tissue and restore pulmonary function; the preclinical program has been completed. This program pursues what has long been considered unattainable: a curative approach to COPD. Our osteoarthritis candidate (HS-101) is intended to achieve true disease modification by repairing and structurally restoring cartilage, synovium, and subchondral bone; most preclinical studies have now been completed.
Exhibit Item Images
-
Product Name : Recombinant human HAPLN1 protein therapeuticWe are developing a recombinant human HAPLN1 (rhHAPLN1) protein therapy with rejuvenative, anti-oxidative, anti-inflammatory, efferocytosis-enhancing, extracellular-matrix-normalizing, and tissue-regenerative activities, intended to treat chronic obstructive pulmonary disease (COPD), osteoarthritis, dry eye disease, and skin aging.
Exhibit Description
We are developing a recombinant human HAPLN1 (rhHAPLN1) protein therapy with rejuvenative, anti-oxidative, anti-inflammatory, efferocytosis-enhancing, extracellular-matrix-normalizing, and tissue-regenerative activities, intended to treat chronic obstructive pulmonary disease (COPD), osteoarthritis, dry eye disease, and skin aging.
Co-Exhibitor or
Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.